METFORMIN IS LINKED TO REDUCED MORTALITY IN TYPE 2 DIABETES WITH COMORBID CKD AND CHF: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i8.1808Keywords:
Chronic kidney disease, Congestive heart failure, Metformin, Mortality, Type 2 diabetesAbstract
Introduction: Due to DM diagnosis criteria, determining its incidence is difficult. Diabetes affects 10.2 million Americans. Due to conflicting data on mortality and antihyperglycemic therapy benefits, managing hyperglycemia in type 2 diabetes mellitus (T2DM) patients at risk of cardiovascular problems is difficult.
The aim: This article showed about metformin is Linked to reduced mortality in type 2 diabetes with comorbid chronic kidney disease (CKD) and congestive heart failure (CHF).
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 85 articles, whereas the results of our search on SagePub brought up 57 articles. The results of the search conducted for the last year of 2013 yielded a total 34 articles for PubMed and 21 articles for SagePub. In the end, we compiled a total of 19 papers, 13 of which came from PubMed and seven of which came from SagePub. We included five research that met the criteria.
Conclusion: Metformin use was found to be related with a reduced risk of death from any cause as well as progression toward ESRD in patients with CKD and CHF in the current investigation.
References
. International Diabetes Federation. Diabetes. Brussels: IDF; 2017.
. Evans K. Diabetic ketoacidosis: update on management. Clin Med. 2019 Sep;19(5):396–8.
. Association AD. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2019. Diabetes Care [Internet]. 2018 Dec 7;42(Supplement_1):S173–81. Available from: https://doi.org/10.2337/dc19-S015
. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2016;62–9.
. Patoulias D, Papadopoulos C, Stavropoulos K, et al. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. J Clin Hypertens. 2020;22(4):562–71.
. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014 Dec;312(24):2668–75.
. Hung S-C, Chang Y-K, Liu J-S, Kuo K-L, Chen Y-H, Hsu C-C, et al. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. lancet Diabetes Endocrinol. 2015 Aug;3(8):605–14.
. Kwon S, Kim YC, Park JY, Lee J, An JN, Kim CT, et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care. 2020 May;43(5):948–55.
. Weir MA, Gomes T, Mamdani M, Juurlink DN, Hackam DG, Mahon JL, et al. Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case-control study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2011 Jun;26(6):1888–94.
. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011 Mar;13(3):221–8.
. Edwards JK. Chronic kidney disease: Metformin increases risk of mortality in patients with advanced chronic kidney disease. Nat Rev Nephrol. 2015 Aug;11(8):443.
. Whitlock RH, Hougen I, Komenda P, Rigatto C, Clemens KK, Tangri N. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study. Mayo Clin Proc. 2020 Jan;95(1):90–100.
. Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, et al. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019 Sep;140(12):1004–14.
. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 May;21(5):1199–208.
. Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Diabetes Metab Syndr Obes. 2011;17(2):187–84.
. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25–33.
. Lalau J-D, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308–22.
. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. Jama. 2016;316(3):313–24.
. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. lancet Diabetes Endocrinol. 2015;3(5):356–66.
. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circ Hear Fail. 2013;6(3):395–402.
. Patel PA, Liang L, Khazanie P, Hammill BG, Fonarow GC, Yancy CW, et al. Antihyperglycemic medication use among Medicare beneficiaries with heart failure, diabetes mellitus, and chronic kidney disease. Circ Hear Fail. 2016;9(7):e002638.
. Roussel R, Travert F, Pasquet B, Wilson PWF, Smith SC, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892–9.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
